Could less chemo be better for brain lymphoma? major trial seeks answers
NCT ID NCT04931368
First seen Apr 01, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This study tests whether a reduced-intensity chemotherapy regimen works better than the standard treatment for people newly diagnosed with primary CNS lymphoma, a rare brain cancer. About 331 adults aged 18 to 70 will receive either the standard MATRix protocol or a milder version. The goal is to see if the gentler approach improves how long patients stay free of major events like progression or severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum Stuttgart
Stuttgart, Baden-Wurttemberg, 70174, Germany
Conditions
Explore the condition pages connected to this study.